Insulet Target of Unusually High Options Trading (PODD)

Insulet Co. (NASDAQ:PODD) was the target of unusually large options trading activity on Wednesday. Stock traders bought 2,000 call options on the company. This is an increase of 3,409% compared to the typical daily volume of 57 call options.

A number of equities analysts recently commented on the stock. Jefferies Group raised their price target on shares of Insulet from $58.00 to $67.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Canaccord Genuity raised shares of Insulet from a “hold” rating to a “buy” rating and raised their price target for the stock from $50.00 to $65.00 in a research report on Wednesday, November 1st. Raymond James Financial raised shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research report on Monday, January 8th. Zacks Investment Research raised shares of Insulet from a “sell” rating to a “hold” rating in a research report on Thursday, February 1st. Finally, UBS Group raised shares of Insulet from a “market perform” rating to an “outperform” rating in a research report on Monday, January 8th. Eight investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $62.53.

Shares of Insulet (PODD) opened at $72.75 on Friday. The stock has a market cap of $4,400.16, a PE ratio of -146.22 and a beta of 1.59. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88. Insulet has a one year low of $38.43 and a one year high of $78.65.

In other Insulet news, Director James C. Mullen purchased 2,500 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were acquired at an average cost of $67.45 per share, with a total value of $168,625.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.90% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the business. Cerebellum GP LLC acquired a new stake in Insulet during the fourth quarter worth about $122,000. Equitec Specialists LLC acquired a new stake in Insulet during the fourth quarter worth about $145,000. C M Bidwell & Associates Ltd. acquired a new stake in Insulet during the fourth quarter worth about $188,000. Diversified Trust Co acquired a new stake in Insulet during the fourth quarter worth about $218,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Insulet by 42.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,283 shares of the medical instruments supplier’s stock worth $227,000 after buying an additional 981 shares in the last quarter.

WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/10/insulet-target-of-unusually-high-options-trading-podd.html.

Insulet Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply